Dr Christoph Hagemeyer obtained a PhD in Biochemistry from the University of Freiburg (Germany) for a thesis on steroid metabolism in the rodent brain. He changed his focus of research from neuroscience to cardiovascular science in 2002 and since then has mainly worked in the field of scFv technology, developing fusion proteins for improved and safer anticoagulation and thrombolysis. He extended his research interests to molecular imaging in 2004 after receiving a Fellowship from the “Centre national de la recherché scientifique” at the University of Bordeaux (France) to undertake studies in magnetic resonance imaging. He moved to Australia in 2005 and is currently Head of the NanoBiotechnology Laboratory at Monash University in Melbourne. His main research interests are drug delivery, molecular imaging and novel bioconjugation techniques in cardiovascular disease, inflammation and cancer.